Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilberto De Lima Lopes

Showing results (41-50 of 91) with videos related to

Pageof 10
Sort By:
Breast Cancer Research and Treatment|May 8, 2015
VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysisLucas Vieira dos Santos, Marcelo Rocha Cruz, Gilberto de Lima Lopes, et al.
The Oncologist|December 30, 2017
The Concept of Biosimilars: From Characterization to Evolution-A Narrative ReviewFadi Farhat, Alfredo Torres, Wungki Park, et al.
JAMA Oncology|June 1, 2018
Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung CancerPedro N Aguiar, Benjamin Haaland, Wungki Park, et al.
Frontiers in Oncology|April 7, 2023
Efficacy and outcomes of ramucirumab and docetaxel in patients with metastatic non-small cell lung cancer after disease progression on immune checkpoint inhibitor therapy: Results of a monocentric, retrospective analysisSamuel A Kareff, Kunal Gawri, Khadeja Khan, et al.
Einstein (Sao Paulo, Brazil)|November 2, 2017
Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancerPedro Nazareth Aguiar, Carmélia Maria Noia Barreto, Bárbara de Souza Gutierres, et al.
Immunotherapy|November 19, 2019
Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USAMin Huang, Gilberto de Lima Lopes, Ralph P Insinga, et al.
International Journal of Radiation Oncology, Biology, Physics|July 19, 2014
Economic analyses in squamous cell carcinoma of the head and neck: a review of the literature from a clinical perspectiveJonas A de Souza, Iuri A Santana, Gilberto de Castro, et al.
Cancers|June 2, 2021
Comparative Efficacy and Safety of Programmed Death-1 Pathway Inhibitors in Advanced Gastroesophageal Cancers: A Systematic Review and Network Meta-Analysis of Phase III Clinical TrialsLaercio Lopes da Silva, Pedro Nazareth Aguiar, Robin Park, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2019
Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular CarcinomaEnrique Soto-Perez-de-Celis, Pedro N Aguiar, Mónica L Cordón, et al.
Cancer|July 28, 2011
Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lungGilberto de Lima Lopes, Joel E Segel, Daniel S W Tan, et al.
Pageof 10

Showing results (41-50 of 91) with videos related to

Sort By:
Pageof 10
Breast Cancer Research and Treatment|May 8, 2015
VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysisLucas Vieira dos Santos, Marcelo Rocha Cruz, Gilberto de Lima Lopes, et al.
The Oncologist|December 30, 2017
The Concept of Biosimilars: From Characterization to Evolution-A Narrative ReviewFadi Farhat, Alfredo Torres, Wungki Park, et al.
JAMA Oncology|June 1, 2018
Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung CancerPedro N Aguiar, Benjamin Haaland, Wungki Park, et al.
Frontiers in Oncology|April 7, 2023
Efficacy and outcomes of ramucirumab and docetaxel in patients with metastatic non-small cell lung cancer after disease progression on immune checkpoint inhibitor therapy: Results of a monocentric, retrospective analysisSamuel A Kareff, Kunal Gawri, Khadeja Khan, et al.
Einstein (Sao Paulo, Brazil)|November 2, 2017
Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancerPedro Nazareth Aguiar, Carmélia Maria Noia Barreto, Bárbara de Souza Gutierres, et al.
Immunotherapy|November 19, 2019
Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USAMin Huang, Gilberto de Lima Lopes, Ralph P Insinga, et al.
International Journal of Radiation Oncology, Biology, Physics|July 19, 2014
Economic analyses in squamous cell carcinoma of the head and neck: a review of the literature from a clinical perspectiveJonas A de Souza, Iuri A Santana, Gilberto de Castro, et al.
Cancers|June 2, 2021
Comparative Efficacy and Safety of Programmed Death-1 Pathway Inhibitors in Advanced Gastroesophageal Cancers: A Systematic Review and Network Meta-Analysis of Phase III Clinical TrialsLaercio Lopes da Silva, Pedro Nazareth Aguiar, Robin Park, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2019
Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular CarcinomaEnrique Soto-Perez-de-Celis, Pedro N Aguiar, Mónica L Cordón, et al.
Cancer|July 28, 2011
Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lungGilberto de Lima Lopes, Joel E Segel, Daniel S W Tan, et al.
Pageof 10